Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler's health, child's health, and pet's health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Pivotal Therapeutics (OTCMKTS:PVTTF) Frequently Asked Questions
What is Pivotal Therapeutics' stock symbol?
Pivotal Therapeutics trades on the OTCMKTS under the ticker symbol "PVTTF."
Has Pivotal Therapeutics been receiving favorable news coverage?
News headlines about PVTTF stock have trended positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pivotal Therapeutics earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Pivotal Therapeutics.
Who are some of Pivotal Therapeutics' key competitors?
Some companies that are related to Pivotal Therapeutics include Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Capstone Therapeutics (CAPS), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Mereo BioPharma Group (MREO), Myrexis (MYRX), Pivot Pharmaceuticals (PVOTF) and Poniard Pharmaceuticals (PARD).
Who are Pivotal Therapeutics' key executives?
Pivotal Therapeutics' management team includes the folowing people:
- Ms. Rachelle MacSweeney, Co-Founder, CEO, Pres & Director
- Mr. George Jackowski, Co-Founder, Chief Scientific Officer & Director (Age 68)
How do I buy shares of Pivotal Therapeutics?
Shares of PVTTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pivotal Therapeutics' stock price today?
One share of PVTTF stock can currently be purchased for approximately $0.00.
MarketBeat Community Rating for Pivotal Therapeutics (OTCMKTS PVTTF)
MarketBeat's community ratings are surveys of what our community members think about Pivotal Therapeutics and other stocks. Vote "Outperform" if you believe PVTTF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PVTTF will underperform the S&P 500 over the long term. You may vote once every thirty days.
